ArticleJournal of physiology and biochemistry2026
The anti-obesity and hepatoprotective effects of bacterial cyclodipeptides in a rat obesity model involve aquaporins, inflammatory factors, and GAB1 modulation.
Article in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Obesity is a major risk factor for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its progressive form, Metabolic Dysfunction-Associated Steatohepatitis (MASH). Bacterial cyclodipeptides (CDPs) have previously been shown to modulate PI3K/Akt/mTOR signaling and transcriptional programs involved in lipid and cholesterol metabolism, highlighting their potential to regulate metabolic homeostasis. Given the central role of the PI3K/Akt/FoxO1 pathway in regulating aquaporins, inflammatory cytokines, and metabolic homeostasis during obesity and MASLD, the therapeutic potential of CDPs was evaluated in a rat model of MASLD. Treatment of obese animals with CDPs decreased body weight and abdominal and thoracic circumferences. The obesogenic diet induced liver damage after the 34th week, which was alleviated by ten weeks of CDP treatment administered three times a week. This reduced the number and size of lipid droplets and inflammatory infiltrates. Additionally, CDPs improved parameters associated with atherogenic dyslipidemia and metabolic dysfunction, including triglycerides and cholesterol, as well as hepatic injury markers. These changes were accompanied by restoration of mitochondrial membrane potential and a significant reduction in mitochondrial ROS generation. CDP treatment in obese animals restored protein expression levels of aquaporins AQP1, AQP5, AQP8, and AQP9 and downregulated the expression of the inflammatory markers NF-κB and IL-1β. Interestingly, the downstream cellular mediator GAB1 from the PI3K/Akt/FoxO1 pathway was also downregulated. These findings demonstrate that CDP treatment restored the expression of glycerol/water transporting aquaporins altered during obesity and MASLD. Overall, CDPs ameliorated MASLD in obese animals through coordinated modulation of lipid metabolism, mitochondrial function, aquaporin expression, and PI3K/Akt/FoxO1 signaling associated with inflammation, supporting their potential as therapeutic candidates for metabolic liver disease.
Indexed as
Identifiers
42584511What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.